BVMF
BALM3
Market cap37mUSD
Oct 20, Last price
22.00BRL
1D
0.00%
1Q
-15.38%
Name
Baumer SA
Chart & performance
P/E
11.93
P/S
1.01
EPS
1.84
Vol. 1Y
87.10%
Shs. 5Y
—
Rev. 5Y
-8.09%
Div Yld LY
20.45%
Div Yld TTM
17.68%
Revenues
214m
+9.95%
Net income
18m
-42.81%
CFO
67m
+113.62%
Dividend
May 04, 20260.82 BRL/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Baumer SA engages in the development, manufacture, and sale of hospital, odontology, and health industry solutions and equipment. It operates through the following segments: Orthopedics, Hospital, Genius, and Castanho. The Orthopedics segment manufactures and sells orthopedic implants and instruments. The Hospital segment manufactures and markets equipment for hospitals. pharmaceutical, chemical, cosmetic, and food industry. The Genius segment deals with biomaterials area. The Castanho segment provides equipment for hospital, industrial, and hotel laundry. The company was founded by Manoel Amaral Baumer in July, 1952 and is headquartered in Mogi Mirim, Brazil.
Key people
Manoel Amaral Baumer
Chairman of the Board, Member of the Executive Board · since 2011
Ruy Salvari Baumer
Chief Executive Officer, Vice Chairman of the Board, Member of the Executive Board · since 2011
Jose Henrique Marques Camargo
Director of Sales · since 2014
Breno Correa Farago
Chief Industrial Officer, Member of the Executive Board · since 2014
Edson Aprigio Lopes de Mattos
Member of the Executive Board · since 2011
Lourdes Maria Araujo Quaresma de Camargo
Chief Technology Officer, Member of the Executive Board · since 2014
Monica Salvari Baumer
Member of the Executive Board · since 2004
Jorge Antonio Barbosa
Director · since 2011
Maria Cristina Baumer Azevedo
Director · since 2004
Joao Carlos Corsini Gamboa
Director · since 2004
Lupercio Tiseo
Director · since 2004
Valuation
Title BRL in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||